<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985855</url>
  </required_header>
  <id_info>
    <org_study_id>2008-03</org_study_id>
    <secondary_id>2008-005013-21</secondary_id>
    <nct_id>NCT00985855</nct_id>
  </id_info>
  <brief_title>Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer</brief_title>
  <official_title>Feasibility of Cetuximab (ERBITUX®) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, randomised, controlled, non comparative study with 2 parallel groups:&#xD;
&#xD;
        -  Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed&#xD;
           by a concomitant radio-chemotherapy including 2 cycles of cisplatin and vinorelbine&#xD;
           associated with a weekly cetuximab infusion during the radiotherapy.&#xD;
&#xD;
        -  Arm B: patients will receive induction chemotherapy (cisplatin and docetaxel) followed&#xD;
           by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide&#xD;
           associated with a weekly cetuximab infusion during the radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patients presenting at least one toxicity grade≥3 (excepted hematological toxicity and nausea-vomiting)</measure>
    <time_frame>End of concomitant treatment (Day 71)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cisplatin, vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin, etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, vinorlebine, cetuximab</intervention_name>
    <description>patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71</description>
    <arm_group_label>Cisplatin, vinorelbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatine, etoposide, cetuximab</intervention_name>
    <description>patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71</description>
    <arm_group_label>Cisplatin, etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-Small-Cell Lung cancer cytologically or histologically proved&#xD;
&#xD;
          -  Stage III AN2 inoperable or non resectable&#xD;
&#xD;
          -  presence of at least one one dimension measurable target (at least 10 mm with spiral&#xD;
             tomodensitometry)&#xD;
&#xD;
          -  Possibility to include all targets in one irradiation field&#xD;
&#xD;
          -  Age of 18 to 70&#xD;
&#xD;
          -  Patients non previously treated&#xD;
&#xD;
          -  Performance Status 0 or 1&#xD;
&#xD;
          -  Loss of weight ≤10% in the 3 last months&#xD;
&#xD;
          -  Neutrophil ≥ 1500/mm3 and platelets ≥ 100000/mm3&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 ml/min&#xD;
&#xD;
          -  total bilirubin ≤ 1,5N and ASAT ALAT ≤ 2,5N&#xD;
&#xD;
          -  Respiratory function normal: VEMS ≥ 40% theorical, DLCO/VA ≥ 50% theorical and PaO2 ≥&#xD;
             60 mmHg&#xD;
&#xD;
          -  Signed inform consent form&#xD;
&#xD;
          -  Compliance to radiotherapy 66 Gy with dosimetry V20 ≤ 35% and pulmonary mean dose≤20&#xD;
             Gy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pretreated bronchial carcinoma, excepted endoscopic deobstruction&#xD;
&#xD;
          -  operable bronchial carcinoma&#xD;
&#xD;
          -  small cell lung cancer, composite cancer, neuroendocrine cancer, broncho alveolar&#xD;
             cancer&#xD;
&#xD;
          -  superior vena cava syndroms&#xD;
&#xD;
          -  puncturable pleural effusion&#xD;
&#xD;
          -  metastatic lung cancer&#xD;
&#xD;
          -  Stage IIIb cancer with neoplastic pericarditis&#xD;
&#xD;
          -  Previous thoracic irradiation&#xD;
&#xD;
          -  severe cardiac disease in the 12 months before inclusion&#xD;
&#xD;
          -  interstitial lung disease&#xD;
&#xD;
          -  anti-EGFR and anti-VEGF treatments&#xD;
&#xD;
          -  hypersensitivity to murine proteins and allergies to protocol drugs&#xD;
&#xD;
          -  uncontrolled infectious state&#xD;
&#xD;
          -  HIV patient&#xD;
&#xD;
          -  corticoid definitive contraindication&#xD;
&#xD;
          -  péripheric neuropathy grade≥2&#xD;
&#xD;
          -  neurologic, psychiatric and organic disorder&#xD;
&#xD;
          -  past or concomitant cancer excepted treated skin baso-cellular cancer or in situ&#xD;
             cervical cancer, or any cancer only surgically treated for 5 years&#xD;
&#xD;
          -  breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FOURNEL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

